Proposed $400 Million Settlement Could Offer Payouts for Generic Prescription Drug Purchases

Rapid City, SD, October 4, 2026 — A proposed $400 million settlement could provide financial recourse for individuals in South Dakota who purchased specific generic prescription drugs during a defined period. The settlement, which is currently under consideration by a federal court, aims to resolve allegations of price fixing involving Sandoz Inc. and Fougera Pharmaceuticals Inc.

The legal action centers on claims that the pharmaceutical companies engaged in practices that inflated the prices of generic prescription medications. Consumers who bought certain generic prescription drugs between May 2009 and December 2019 may be eligible to receive a portion of the settlement funds, should it be approved by the court.

Details regarding the specific generic prescription drugs covered by the settlement, the precise eligibility criteria for claimants, and the process for submitting claims have not yet been fully detailed. Information regarding the timeline for potential payouts and the finalization of the court’s decision is also pending.

The companies involved, Sandoz Inc. and Fougera Pharmaceuticals Inc., are named defendants in the litigation. The allegations of price fixing are being reviewed by the federal court to determine the validity of the claims and the fairness of the proposed settlement terms.

Further information concerning eligibility, claim forms, and the settlement’s approval status is expected to be released as the federal court proceeds with its review. Residents of South Dakota who believe they may qualify are advised to await official announcements and instructions from the court or legal representatives managing the settlement.

Story summarized from the original created by Tamara Chibe on www.kotatv.com, see more information here.

Media gallery